{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '7.2.6.', 'Quality of Life Procedures', '64', '7.2.7.', 'Biomarker Procedures', '65', '7.2.7.1.', 'Tumor Samples', '65', '7.2.7.2.', 'Serum/Plasma Samples', '65', '7.2.7.3.', 'Peripheral Blood Mononuclear Cells (optional)', '65', '7.2.8.', 'Future Biomedical Research', '66', '7.2.8.1.', 'Genomics Sub-study - Optional', '66', '8.', 'STUDY TREATMENTS', '66', '8.1.', 'Investigational and Reference Treatments', '66', '8.1.1.', 'Experimental Group Treatment (Cemiplimab)', '67', '8.1.2.', \"Control Group Treatments (Investigator's Choice)\", '67', '8.1.2.1.', 'Pemetrexed, Alimta R', '68', '8.1.2.2.', 'Topotecan', '69', '8.1.2.3.', 'Irinotecan', '69', '8.1.2.4.', 'Gemcitabine, GemzarR', '70', '8.1.2.5.', 'Vinorelbine', '70', '8.2.', 'Pretreatments', '71', '8.3.', 'Dose Modification and Study Treatment Discontinuation Rules for', 'Cemiplimab', '71', '8.3.1.', 'Dose Modification', '72', '8.3.2.', 'Immune-Related Adverse Events (irAEs)', '74', '8.3.3.', 'Resumption of Cemiplimab After Treatment Hold, or Discontinuation', '76', '8.4.', 'Dose Modification and Study Treatment Discontinuation Rules for', \"Investigator's Choice Chemotherapy\", '76', '8.4.1.', 'Pemetrexed Dose Modifications', '76', '8.4.2.', 'Topotecan Dose Modifications', '77', '8.4.3.', 'Irinotecan Dose Modifications', '78', '8.4.4.', 'Gemcitabine Dose Modifications', '80', '8.4.5.', 'Vinorelbine Dose Modifications', '81', '8.5.', 'Study Treatment Discontinuation Rules, General Guidance', '82', '8.5.1.', 'Study Drug Discontinuation', '82', '8.5.1.1.', 'Reasons for Permanent Discontinuation of Study Treatment', '82', '8.6.', 'Treatment Beyond Progression in the Cemiplimab Treatment Group', '82', 'Regeneron Pharmaceuticals, Inc.', 'Page 22 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '8.7.', 'Management of Acute Reactions', '83', '8.7.1.', 'Acute Infusion Reactions', '83', '8.7.1.1.', 'Interruption of the Infusion', '84', '8.7.1.2.', 'Termination of the Infusion', '84', '8.8.', 'Method of Treatment Assignment', '85', '8.8.1.', 'Blinding', '85', '8.9.', 'Treatment Logistics and Accountability', '86', '8.9.1.', 'Packaging, Labeling, and Storage', '86', '8.9.2.', 'Supply and Disposition of Treatments', '86', '8.9.3.', 'Treatment Accountability', '86', '8.9.4.', 'Treatment Compliance', '86', '8.10.', 'Concomitant Medications and Procedures', '86', '8.10.1.', 'Prohibited Medications and Procedures', '86', '8.10.2.', 'Permitted Medications and Procedures', '87', '9.', 'SAFETY DEFINITIONS, REPORTING, AND MONITORING', '87', '9.1.', 'Obligations of Investigator', '87', '9.2.', 'Obligations of Sponsor', '87', '9.3.', 'Definitions', '88', '9.3.1.', 'Adverse Event', '88', '9.3.2.', 'Serious Adverse Event', '88', '9.3.3.', 'Adverse Events of Special Interest', '89', '9.3.4.', 'Infusion Reactions', '89', '9.4.', 'Recording and Reporting Adverse Events', '89', '9.4.1.', 'Adverse Events', '89', '9.4.2.', 'Serious Adverse Events', '90', '9.4.3.', 'Other Events that Require Accelerated Reporting to Sponsor', '90', '9.4.3.1.', 'Immune-Related Adverse Events', '91', '9.4.4.', 'Reporting Adverse Events Leading to Withdrawal from the Study', '91', '9.4.5.', 'Abnormal Laboratory, Vital Signs, or Electrocardiogram Results', '91', '9.4.6.', 'Follow-up', '91', '9.5.', 'Evaluation of Severity and Causality', '92', '9.5.1.', 'Evaluation of Severity', '92', '9.5.2.', 'Evaluation of Causality', '92', 'Regeneron Pharmaceuticals, Inc.', 'Page 23 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}